|1.||Golde, Todd E: 3 articles (04/2014 - 06/2008)|
|2.||Ladd, Thomas B: 3 articles (04/2014 - 06/2008)|
|3.||Koo, Edward H: 3 articles (04/2014 - 06/2008)|
|4.||Li, Yue-Ming: 2 articles (08/2015 - 04/2013)|
|5.||Bales, Kelly R: 2 articles (05/2015 - 04/2013)|
|6.||Pettersson, Martin: 2 articles (05/2015 - 04/2013)|
|7.||Johnson, Douglas S: 2 articles (05/2015 - 04/2013)|
|8.||Am Ende, Christopher W: 2 articles (05/2015 - 04/2013)|
|9.||Li, Chuang: 2 articles (11/2014 - 03/2014)|
|10.||Liu, Ying: 2 articles (11/2014 - 03/2014)|
|1.||Hepatocellular Carcinoma (Hepatoma)
03/11/2014 - "Tumor response was evaluated by contrast enhanced CT using modified Response Evaluation Criteria in Solid Tumors (mRECIST) after 1-, 6- and 12-month of initial rAd-p53 combined with GSMs -TAE. "
01/01/2012 - "GSMs are aggressive tumors that have a temporal lobe predilection, but they may present anywhere in the brain. "
02/18/2015 - "Intravenous injection of GSMs into tumor-bearing mice led to selective tumoral accumulation, enabling magnetic resonance (MR) imaging of tumor margins. "
11/01/2014 - "Compared with HAI, GSMs-TACE has higher epirubicin concentrations in tumor and lower concentrations in plasma. "
11/01/2014 - "The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively. "
|3.||Alzheimer Disease (Alzheimer's Disease)
09/21/2012 - "GSMs are promising agents for treatment or prevention of Alzheimer's disease. "
04/01/2012 - "GSMs may be superior to GSIs in the treatment of Alzheimer's disease not only by sparing Notch signaling but also by avoiding Aβ-rebound."
05/14/2015 - "Herein we describe the design and synthesis of a series of pyridopyrazine-1,6-dione γ-secretase modulators (GSMs) for Alzheimer's disease (AD) that achieve good alignment of potency, metabolic stability, and low MDR efflux ratios, while also maintaining favorable physicochemical properties. "
12/01/2013 - "γ-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. "
09/01/2013 - "Aggregation and accumulation of Aβ42 play an initiating role in Alzheimer's disease (AD); thus, selective lowering of Aβ42 by γ-secretase modulators (GSMs) remains a promising approach to AD therapy. "
10/01/2000 - "DNA sequence analysis of selected differentially expressed RNA by this procedure using 240 combinations of random primer pairs yielded 41 distinct cDNA sequences: 22 of which have significant sequence homology to previously identified meta-zoan genes, 15 GEMS (genes expressed in monkey neointima), and 4 GSMS (genes suppressed in monkey neointima) that have little homology to reported sequences. "
|3.||Amyloid Precursor Protein Secretases (beta-Secretase)
|5.||Protein Isoforms (Isoforms)
|6.||Complementary DNA (cDNA)
|8.||RNA (Ribonucleic Acid)